Evidence map›Paper›PMID 39050108›Full record

ArticleEClinicalMedicine2024

Changes in the cardiovascular risk profile in children approaching kidney replacement therapy.

Priyanka Khandelwal, Jonas Hofstetter, Karolis Azukaitis, Aysun Bayazit, Anke Doyon, Ali Duzova, Nur Canpolat, Ipek Kaplan Bulut, Lukasz Obryck, Bruno Ranchin and 14 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Priyanka KhandelwalDivision of Pediatric Nephrology, UCL Great Ormond Street Hospital and Institute of Child Health, London, UK.
Jonas HofstetterCenter for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Karolis AzukaitisClinic of Pediatrics, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.
Aysun BayazitDepartment of Pediatric Nephrology, School of Medicine, Cukurova University, Adana, Türkiye.
Anke DoyonCenter for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Ali DuzovaDivision of Pediatric Nephrology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
Nur CanpolatDivision of Pediatric Nephrology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Türkiye.
Ipek Kaplan BulutDepartment of Pediatric Nephrology, Ege University Faculty of Medicine, Izmir, Türkiye.
Lukasz ObryckDepartment of Nephrology, Kidney Transplantation and Arterial Hypertension, The Children's Memorial Health Institute, Warsaw, Poland.
Bruno RanchinPediatric Nephrology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Université de Lyon, Lyon, France.
Dusan ParipovicDepartment of Pediatric Nephrology, University Children's Hospital, Belgrade, Serbia.
Sevcan BakkalogluPediatric Nephrology Unit, Gazi University Hospital, Ankara, Türkiye.
Harika AlpayDepartment of Pediatric Nephrology, Marmara University Medical School, Istanbul, Türkiye.
Klaus ArbeiterDivision of Pediatric Nephrology and Gastroenterology, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Mieczyslaw LitwinDepartment of Nephrology, Kidney Transplantation and Arterial Hypertension, The Children's Memorial Health Institute, Warsaw, Poland.
Ariane ZaloszycPediatric Nephrology Unit, Hautepierre University Hospital, Strasbourg, France.
Fabio PaglialongaPediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Dagmara Borzych-DużałkaPediatric Nephrology Unit, Medical University of Gdansk, Gdansk, Poland.
Claus Peter SchmittCenter for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Anette MelkDepartment of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany.
Uwe QuerfeldDepartment of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité Universitätsmedizin, Berlin, Germany.
Franz SchaeferCenter for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Rukshana ShroffDivision of Pediatric Nephrology, UCL Great Ormond Street Hospital and Institute of Child Health, London, UK.
4C and 3H study investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite significant cardiovascular (CV) morbidity in children on dialysis and after kidney transplantation, data on the evolution of CV damage in children with chronic kidney disease (CKD) approaching kidney replacement therapy (KRT) is unknown. Methods: The burden, progression, and predictors of CV damage before KRT onset were explored in two prospective multicenter cohorts from Europe and Canada: Cardiovascular Comorbidity in Children with CKD (4C) and Haemodiafiltration, Heart and Height (3H) studies, conducted from 2009-19 and 2013-16, respectively. CV damage and risk factors were evaluated (i) cross sectionally at KRT-start (n = 248), and (ii) longitudinally over the 2-years preceding KRT start (n = 157; 331 patient-visits). Longitudinal analyses with mixed-effects models estimated associations of modifiable CV risk factors with change in carotid intima-media thickness (cIMT) standard deviation score (SDS), pulse wave velocity (PWV-SDS), left ventricular (LV) mass and systolic dysfunction. Findings: 248 patients, age 14.3 (12.2, 16.2) years were evaluated at median 35 (28-114) days before KRT start. Elevated cIMT-SDS and PWV-SDS were present in 43% and 25%, and LV hypertrophy and systolic dysfunction in 49% and 33%. Aortic stiffness and LV hypertrophy significantly increased, especially in the year before KRT start (adjusted odds ratio, OR 0.33, Interpretation: This comprehensive CV evaluation shows the progressive accrual of modifiable risk factors and a high burden of CV damage in the years preceding KRT onset. CV damage in the pre-KRT period is preventable. Funding: Supported by EU4Health Programme (101085068) and Kidney Research UK (RP39/2013).

Indexed as

Carotid intima-media thickness (cIMT)Kidney replacement therapy (KRT)Left ventricular mass index (LVMI)Mid-wall fractional shorteningPulse wave velocity (PWV)

Identifiers

PMID39050108
PMCPMC11268110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.